Views: 2 Author: Site Editor Publish Time: 2022-11-16 Origin: Site
PREJUVA® constitutes a buffered physiological solution of high molecular weight (H-HA) and low molecular weight (L-HA) HA. PREJUVA is the profhilo alternative. The HA, at both high and low molecular weights used in the device, is obtained through a biofermentation process without chemical modification and therefore, resulting in excellent tolerability.
What is PREJUVA made of?
Furthermore, due to a specific and patented treatment of the solution (HYLAFUSE Technology TM), the H-HA and L-HA chains, contained in PREJUVA®, interact with each other providing unique rheological characteristics and thus allowing the administration of higher concentrations of HA without increasing the viscosity.
The formulation of HA with different molecular weights contained in PREJUVA® is aimed at counteracting the physiological reduction of HA in the skin, restoring hydration, elasticity and skin tone, by associating, in a synergic way, deep
hydration with the mechanical action of lifting the skin.
The other components are: sodium chloride, sodium phosphate and water for injectable preparations.
PREJUVA® acting through a corrective/filling action of natural and induced cutaneous depressions, intervenes:
• in the physiological process of skin aging, the effects of which include reduced skin hydration, the alteration of elastic fibers and collagen of the dermis, with loss of turgor and skin tone;
• in the dermal tissue repair process, in cases of scars resulting from superficial Cutaneous trauma (e.g. acne and chicken pox scars).
The viscoelastic and hydrating properties of HA, combined with the ability to maintain adequate levels of HA in the cutaneous tissues, rehydrate the skin and create optimal conditions for preventing and counteracting the skin aging process white favoring tissue remodeling with a subsequent corrective effect on photo and chrono aging damage and any possible scarring of the skin.
HA also plays a role inside the extracellular matrix, creating the physiological conditions for the proliferation, migration and organization of the dermal cellular component. Moreover, the intradermal administration of PREJUVA® and its action at the dermal layer rather than the epidermal layer, allows an optimal quantity of HA to be brought directly to the tissue being treated, in order to counteract the cytotoxic action of free radicals on the fibroblasts and on the adipose compartments below, ensuring the efficacy of preventive and corrective esthetic medicine treatments.
PREJUVA® is indicated for treatment of the face and body. However, it is particularly indicated for treatment of the malar-zygomatic and submalar areas.
An initial cycle of two treatment sessions at 30 day intervals is recommended, followed if necessary by maintenance treatments every 2 months. However, it is suggested to evaluate the specific PREJUVA® protocol according to the patients degree of aging.